VIP (Vasoactive Intestinal Peptide)
Vasoactive intestinal peptide — a natural signaling molecule used via compounded nasal sprays in some practitioner protocols; evidence for those uses is limited.
What it is
Vasoactive intestinal peptide is a naturally occurring 28-amino-acid signaling molecule with roles across the gut, lungs, immune system and circadian clock. As a therapeutic it has a long, mostly frustrating research history — and a active second life in compounded nasal sprays used by mold-illness (CIRS) protocols.
Synthetic VIP (aviptadil) has been studied for pulmonary hypertension, ARDS and COVID-19 — the last in sizable trials that did not win approval. The nasal-spray practitioner use rests on protocol literature well short of controlled-trial standards.
What researchers have actually studied it for
Pulmonary hypertension, ARDS and COVID-19 (as aviptadil, without approval), plus practitioner mold-illness protocols resting on case-series evidence.
How it works
VIP binds receptors (VPAC1/2) across many tissues: relaxing airway and vascular smooth muscle, damping inflammatory signaling, supporting surfactant-producing lung cells, and modulating immune tone. Its breadth is exactly why bottling it into one marketed use has proven hard.
The molecule itself
A 28-amino-acid member of the secretin/glucagon peptide superfamily, acting on VPAC1/VPAC2 receptors distributed across lung, gut, vascular and immune tissue. Notoriously fragile in circulation — a half-life of minutes — which shaped every therapeutic attempt around delivery.
Where it came from
Discovered in 1970 by Sami Said and Viktor Mutt in gut extracts, VIP spent decades as a physiology celebrity and therapeutic disappointment — fragile in the body, broad in action. Aviptadil's COVID-era trials briefly made it famous; the CIRS protocol community had already adopted compounded nasal VIP years earlier.
The timeline
1970
Isolated by Said and Mutt from intestinal extracts.
1970s–90s
Physiology mapped across systems; therapeutic attempts stumble on fragility.
2000s
Aviptadil explored for pulmonary hypertension; CIRS practitioner protocols adopt nasal VIP.
2020–21
COVID ARDS trials of IV aviptadil; no convincing benefit, no approval.
What the research record actually contains
- Deep physiology literature across lung, gut and immune systems.
- Aviptadil trials in critical COVID-19: no convincing overall benefit; no approval.
- CIRS/mold-protocol nasal use: practitioner case series, not controlled trials.
What could change this assessment
Receptor-selective VPAC agonists and better delivery are the plausible future; native VIP's fragility caps its own prospects. The CIRS community's use will continue regardless, as practitioner medicine does.
What's known about risks
Trial-studied intravenous aviptadil showed manageable, blood-pressure-related effects under monitoring. Compounded nasal-spray use has practitioner-reported tolerability and little controlled characterization; quality rests on the compounding pharmacy.
Where it stands legally
Not an FDA-approved drug; available in practice via compounding channels for practitioner protocols, where eligibility and quality are pharmacy questions.
Worth asking a licensed provider
- 1.For suspected mold-related illness, what does a rigorous work-up look like before protocol medicine?
- 2.What evidence supports nasal VIP for my specific picture — and what would we measure?
- 3.Which pharmacy compounds it, and how is quality verified?
Common claims, corrected
“VIP spray is an approved mold-illness treatment.”
Reality: CIRS protocols are practitioner-developed; their VIP step rests on case series, and no regulatory body has approved VIP for it.
“The COVID trials proved it works for lungs.”
Reality: They tested it seriously and didn't show convincing overall benefit — a run experiment with a mostly negative answer.
VIP (Vasoactive Intestinal Peptide) FAQ
What is VIP nasal spray used for?
Mostly in CIRS/mold-illness protocols as a late-stage step. The supporting evidence is practitioner case series — meaningful to that community, but far from controlled trials.
Did VIP work for COVID?
Aviptadil's sizable trials in critical COVID-19 didn't show convincing overall benefit, and no approval followed.
Is VIP approved anywhere?
No FDA approval exists; access in practice runs through compounding pharmacies under practitioner protocols.
What is CIRS, in one honest paragraph?
Chronic Inflammatory Response Syndrome — a practitioner-defined framework attributing multi-system symptoms to biotoxin exposure, with its own labs and protocol. It has a devoted clinical community and limited mainstream acceptance; both facts belong in any decision.
Why nasal delivery for VIP?
The peptide survives minutes in blood; nasal dosing offers a practical repeated-administration route. Fragility, not targeting, drove the format.